Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-B Pathway in Type 2 Diabetic db/db Mice

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Chen, Xiao Wen ^a   Du, Xiao Yan ^a   Wang, Yu Xian ^a   Wang, Jian Cheng ^a   Liu, Wen Ting ^a   Chen, Wen Jing ^a   Li, Hong Yu ^a   Peng, Fen Fen ^a   Xu, Zhao Zhong ^a   Niu, Hong Xin ^a   Long, Hai Bo ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRBESARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; GLOMERULUS CAPILLARY; KIDNEY FUNCTION; KIDNEY INJURY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; ANIMAL; C57BL MOUSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TETRAZOLES;

EID: 84955514338     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/1405924     Document Type: Article

References (33)

1. E. Ritz and S. R. Orth, "Nephropathy in patients with type 2 diabetes mellitus, " The New England Journal of Medicine, vol. 341, no. 15, pp. 1127-1133, 1999.
2. E. Ritz, I. Rychlik, F. Locatelli, S. Halimi, "End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions, " American Journal of Kidney Diseases, vol. 34, no. 5, pp. 795-808, 1999.
3. A. R. Andersen, J. S. Christiansen, J. K. Andersen, S. Kreiner, T. Deckert, "Diabetic nephropathy in type 1 (insulindependent) diabetes: an epidemiological study, " Diabetologia, vol. 25, no. 6, pp. 496-501, 1983.
4. G. L. Bakris, M. Williams, L. Dworkin et al., "Preserving renal function in adults with hypertension and diabetes: a consensus approach, " American Journal of Kidney Diseases, vol. 36, no. 3, pp. 646-661, 2000.
5. T.W.Meyer, P. H. Bennett, R.G.Nelson, "Podocytenumber predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria, " Diabetologia, vol. 42, no. 11, pp. 1341-1344, 1999.
6. P. Anil Kumar, G. I. Welsh, M. A. Saleem, R. K. Menon, "Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus, " Frontiers in Endocrinology, vol. 5, article 151, 2014.
7. F. Chow, E. Ozols, D. J. Nikolic-Paterson, R. C. Atkins, G. H. Tesch, "Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury, " Kidney International, vol. 65, no. 1, pp. 116-128, 2004.
8. W. H. Yiu, M. Lin, S. C. W. Tang, "Toll-like receptor activation: from renal inflammation to fibrosis, " Kidney International Supplements, vol. 4, no. 1, pp. 20-25, 2014.
9. H. Kanamori, T. Matsubara, A. Mima et al., "Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy, " Biochemical and Biophysical Research Communications, vol. 360, no. 4, pp. 772-777, 2007.
10. B. Amann, R. Tinzmann, B. Angelkort, "ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1, " Diabetes Care, vol. 26, no. 8, pp. 2421-2425, 2003.
11. X. Ren, G.Guan, G. Liu, G. Liu, "Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitiumof diabetic rats, " Pharmacology, vol. 83, no. 2, pp. 80-87, 2009.
12. C. Wang, C. Min, X. Rong, T. Fu, X. Huang, C. Wang, "Irbesartan can improve blood lipid and the kidney function of diabetic nephropathy, " Discovery Medicine, vol. 20, no. 108, pp. 67-77, 2015.
13. S.-I.Masuda, K. Tamura, H.Wakui et al., "Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy, " Hypertension Research, vol. 32, no. 11, pp. 950-955, 2009.
14. M. Nakamura, N. Sasai, I. Hisatome, K. Ichida, "Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes, " Clinical Pharmacology: Advances and Applications, vol. 6, no. 1, pp. 79-86, 2014.
15. A. Hartner, N. Cordasic, B. Klanke et al., "Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress, " Biochimica et Biophysica Acta, vol. 1842, no. 4, pp. 558-565, 2014.
16. S. Chen, G. Jin, K.-M. Huang et al., "Lycorine suppresses ranklinduced osteoclastogenesis in vitro and prevents ovariectomyinduced osteoporosis and titanium particle-induced osteolysis in vivo, " Scientific Reports, vol. 5, Article ID 12853, 2015.
17. U. M. Malyankar, M. Scatena, K. L. Suchland, T. J. Yun, E. A. Clark, C. M. Giachelli, "Osteoprotegerin is an (v)3-induced, NF-B-dependent survival factor for endothelial cells, "The Journal of Biological Chemistry, vol. 275, no. 28, pp. 20959-20962, 2000.
18. S. Liu, W. Shi, H. Xiao et al., "Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury, " PLoS ONE, vol. 7, no. 7, Article IDe41331, 2012.
19. A. Leiherer, A. Muendlein, P. Rein et al., "Genome-wide association study reveals a polymorphism in the podocyte receptor RANK for the decline of renal function in coronary patients, " PLoS ONE, vol. 9, no. 12, Article IDe114240, 2014.
20. S. Kiechl, J. Wittmann, A. Giaccari et al., "Blockade of receptor activator of nuclear factor-B (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus, " Nature Medicine, vol. 19, no. 3, pp. 358-363, 2013.
21. X. Zhong, A. C. K. Chung, H. Y. Chen et al., "MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes, " Diabetologia, vol. 56, no. 3, pp. 663-674, 2013.
22. X. Bai, X. Li, J. Tian, Z. Zhou, "Antiangiogenic treatment diminishes renal injury and dysfunction via regulation of local akt in early experimental diabetes, " PLoS ONE, vol. 9, no. 4, Article ID e96117, 2014.
23. E. Gagliardini, S. Conti, A. Benigni, G. Remuzzi, A. Remuzzi, "Imaging of the porous ultrastructure of the glomerular epithelial filtration slit, " Journal of the American Society of Nephrology, vol. 21, no. 12, pp. 2081-2089, 2010.
24. Y. Zhao, S.-J. Chen, J.-C. Wang et al., "Sesquiterpene lactones inhibit advanced oxidation protein product-induced MCP-1 expression in podocytes via an IKK/NF-B-dependent mechanism, " Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 934058, 13 pages, 2015.
25. Z.-H. Yang and X.-D. Peng, "Insulin resistance and heart injury in rats with insulin resistance or type 2 diabetes mellitus, " Acta Cardiologica, vol. 65, no. 3, pp. 329-335, 2010.
26. M. Degasparo, K. J. Catt, T. Inagami, J.W. Wright, T. Unger, "International union of pharmacology. XXIII. The angiotensin II receptors, " Pharmacological Reviews, vol. 52, no. 3, pp. 415-472, 2000.
27. H.-H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, P. Arner, "The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, "The New England Journal ofMedicine, vol. 345, no. 12, pp. 870-878, 2001.
28. E. J. Lewis, L. G. Hunsicker, W. R. Clarke et al., "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, " The New England Journal of Medicine, vol. 345, no. 12, pp. 851-860, 2001.
29. M. Tunçdemir and M. Oztürk, "The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy, " Acta Histochemica, vol. 113, no. 8, pp. 826-832, 2011.
30. F. Bonnet, M. E. Cooper, H. Kawachi, T. J. Allen, G. Boner, Z. Cao, "Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension, " Diabetologia, vol. 44, no. 7, pp. 874-877, 2001.
31. J. Schrader, W. Rennekamp, U. Niebergall et al., "Cytokineinduced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death, " Diabetologia, vol. 50, no. 6, pp. 1243-1247, 2007.
32. C. Lorz, A. Benito-Martin, A. Boucherot et al., "The death ligand TRAIL in diabetic nephropathy, " Journal of the American Society of Nephrology, vol. 19, no. 5, pp. 904-914, 2008.
33. R. Candido, "Theosteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney, " Current Opinion in Nephrology and Hypertension, vol. 23, no. 1, pp. 69-74, 2014